TetraLogic Pharmaceuticals
365 Phoenixville Pike
Malvern
Pennsylvania
19355
United States
Tel: 610-889-9900
Fax: 610-889-9994
Website: http://www.tetralogicpharma.com/
Email: info@tetralogicpharma.com
69 articles about TetraLogic Pharmaceuticals
-
TetraLogic Announces Completion Of Sale Of SMAC Mimetic And HDAC Inhibitor Assets To Medivir
12/29/2016
-
TetraLogic Announces Agreements To Sell SMAC Mimetic And HDAC Inhibitor Assets To Medivir And To Restructure Its Convertible Senior Notes And Delisting Of Common Stock
11/3/2016
-
TetraLogic Slashes Two-Thirds of Workforce After Mid-Stage Trial Failure
1/25/2016
-
TetraLogic Pharmaceuticals Announces Clinical Data On Birinapant To Be Presented At The 57th Annual American Society of Hematology Annual Meeting
11/9/2015
-
TetraLogic Pharmaceuticals Announces The Opening Of An IND For SHAPE Gel In Alopecia Areata
11/2/2015
-
TetraLogic Pharmaceuticals To Present At The Jefferies and Co. 2015 Hepatitis B Summit
7/29/2015
-
TetraLogic Pharmaceuticals Provides Update On Hepatitis B Clinical Program
7/21/2015
-
TetraLogic Pharmaceuticals Announces Update On MDS Clinical Program
7/1/2015
-
TetraLogic Pharmaceuticals’s New IPO Takes A Hit As Company Halts Hepatitis B Trial
5/7/2015
-
TetraLogic Pharmaceuticals Announces Termination Of Public Offering
5/6/2015
-
TetraLogic Pharmaceuticals Announces Public Offering Of Common Stock
5/1/2015
-
TetraLogic Pharmaceuticals Announces Pricing Of $25 Million Public Offering
5/1/2015
-
TetraLogic Pharmaceuticals Announces Publication Of Two Papers Describing Birinapant's Preclinical Activity In Chronic Hepatitis B
4/21/2015
-
TetraLogic Pharmaceuticals And Merck & Co. To Collaborate On The Evaluation Of Birinapant In Combination With KEYTRUDA (Pembrolizumab) In Solid Tumors
4/20/2015
-
TetraLogic Pharmaceuticals To Present At The 14th Annual Needham Healthcare Conference
4/9/2015
-
TetraLogic Pharmaceuticals Reports 2014 Financial Results And Provides Clinical Programs Update
2/27/2015
-
TetraLogic Pharmaceuticals Announces Initiation Of A Randomized Phase 2 Clinical Trial Of SHAPE In Subjects With Cutaneous T-Cell Lymphoma
12/18/2014
-
TetraLogic Pharmaceuticals Provides Update On Ovarian Cancer Study
12/16/2014
-
TetraLogic Pharmaceuticals To Participate In Two Conferences in December
12/5/2014
-
TetraLogic Pharmaceuticals Announces Clinical Data On Birinapant To Be Presented At The 56th Annual American Society of Hematology Annual Meeting
12/5/2014